PRME supply chain intelligence for Prime Medicine, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Prime Medicine, Inc. (PRME) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AAV-REAGENT-PRODUCTION-CORE | AAV-REAGENT-PRODUCTION-CORE | 90% | We use our internal AAV Reagent Production Core, analytical development team, as well as outsourced resources and partners to generate AAV Prime Editors, quality control test as well as characterize them. |
| OUTSOURCED-RESOURCES-AND-PARTNERS | OUTSOURCED-RESOURCES-AND-PARTNERS | 90% | We use our internal AAV Reagent Production Core, analytical development team, as well as outsourced resources and partners to generate AAV Prime Editors, quality control test as well as characterize them. |
| BEAM-THERAPEUTICS-INC | BEAM-THERAPEUTICS-INC | 75% | The Company is currently engaged in arbitration proceedings with Beam Therapeutics, Inc., or Beam, regarding the parties’ collaboration and license agreement |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from PRME graph: Reciprocal relationship from CRBU graph: Reciprocal relationship from PRME graph: tic effect in such experiments or s… |
| CRBU | Caribou Biosciences, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| CRSP | CRISPR Therapeutics AG | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from PRME graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from PRME graph: tic effect in such experiments or s… |
| DTIL | Precision BioSciences, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| EDIT | Editas Medicine, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from PRME graph: Reciprocal relationship from EDIT graph: Reciprocal relationship from PRME graph: Reciprocal relationship from EDIT g… |
| LLY | Eli Lilly and Company | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from PRME graph: Reciprocal relationship from LLY graph: Reciprocal relationship from PRME graph: Reciprocal relationship from LLY grap… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from LXEO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from LXEO g… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from PRME graph: ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and ma… |
| MYGN | Myriad Genetics, Inc. | 72% | ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop and our technology. However, we may not … |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| NTLA | Intellia Therapeutics, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from SGMO g… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from PRME graph: ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and m… |
| SNYNF | Sanofi | 72% | ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop and our technology. However, we may not … |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| JUNO-THERAPEUTICS-INC | JUNO-THERAPEUTICS-INC | 90% | Supplemental information related to the Research Collaboration and License Agreement, or the BMS Collaboration Agreement, with Juno Therapeutics, Inc., a wholly-owned subsidiary of the Bristol-Myers … |
| BEAM | Beam Therapeutics Inc. | 72% | Reciprocal relationship from BEAM graph: Reciprocal relationship from PRME graph: orm is expected to allow Prime Medicine to generate follow-on candidates rapidly and efficiently. In addition, we are… |
| BEAM | Beam Therapeutics Inc. | 72% | orm is expected to allow Prime Medicine to generate follow-on candidates rapidly and efficiently. In addition, we are identifying partnership opportunities to advance other programs. CGD, is our most… |
| BMY | Bristol-Myers Squibb Company | 72% | Reciprocal relationship from BMY graph: Reciprocal relationship from PRME graph: presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 202… |
| BMY | Bristol-Myers Squibb Company | 72% | presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027.… |
| BMYMP | Bristol-Myers Squibb Co | 72% | Reciprocal relationship from BMYMP graph: Reciprocal relationship from PRME graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from PRME graph: Reciprocal relationship from BMYM… |
| BMYMP | Bristol-Myers Squibb Co | 72% | presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027.… |
| CRBU | Caribou Biosciences, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| CRBU | Caribou Biosciences, Inc. | 72% | Reciprocal relationship from CRBU graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| CRSP | CRISPR Therapeutics AG | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| CRSP | CRISPR Therapeutics AG | 72% | Reciprocal relationship from CRSP graph: Reciprocal relationship from PRME graph: Reciprocal relationship from CRSP graph: Reciprocal relationship from PRME graph: tic effect in such experiments or s… |
| DTIL | Precision BioSciences, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| DTIL | Precision BioSciences, Inc. | 72% | Reciprocal relationship from DTIL graph: Reciprocal relationship from PRME graph: Reciprocal relationship from DTIL graph: Reciprocal relationship from PRME graph: Reciprocal relationship from DTIL g… |
| EDIT | Editas Medicine, Inc. | 72% | Reciprocal relationship from EDIT graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| EDIT | Editas Medicine, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| LLY | Eli Lilly and Company | 72% | Reciprocal relationship from LLY graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates … |
| LLY | Eli Lilly and Company | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| LXEO | Lexeo Therapeutics, Inc. | 72% | Reciprocal relationship from LXEO graph: ply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reaso… |
| MYGN | Myriad Genetics, Inc. | 72% | ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop and our technology. However, we may not … |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from PRME graph: ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and ma… |
| NTLA | Intellia Therapeutics, Inc. | 72% | Reciprocal relationship from NTLA graph: Reciprocal relationship from PRME graph: tic effect in such experiments or studies or they may have other characteristics that may make the product candidates… |
| NTLA | Intellia Therapeutics, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from SGMO graph: Reciprocal relationship from PRME graph: Reciprocal relationship from SGMO g… |
| SGMO | Sangamo Therapeutics, Inc. | 72% | tic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable, or unlikely to receive marketing approv… |
| SNYNF | Sanofi | 72% | ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and marketing product candidates we may develop and our technology. However, we may not … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from PRME graph: ght. We also could be required to obtain a license from such third party to continue developing, manufacturing and m… |
| K-EMERGING-GROWTH-COMPANY | K-EMERGING-GROWTH-COMPANY | 62% | ed as prepaid expenses and other current assets. If the expenses incurred exceed payments made, the difference is reflected as accrued expenses and other current liabilities. Non-refundable advance p… |
| Q-EMERGING-GROWTH-COMPANY | Q-EMERGING-GROWTH-COMPANY | 62% | r 2024. These were offset by: • $10.7 million of non-cash amounts included in net loss, which primarily consisted of stock-based compensation expense, non-cash lease expense, depreciation and amortiz… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| PRME-DEBT-11894 | Warrants outstanding: 18800000 | 90% | xbrl warrant detail from xbrl 2024-12-31. |
| PRME-DEBT | Debt stack $114.5M | 90% | Market cache reports total debt of $114.5M. |
| PRME-DEBT-11895 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2022-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| PRME-OWNER-ALPHABET-INC | Alphabet Inc. | 90% | 13F overlay lists Alphabet Inc. as top holder; 194 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['customer'] |
| JANX | Janux Therapeutics, Inc. | 100.00 | 2 | |
| SDGR | Schrödinger, Inc. | 100.00 | 2 | |
| CLLS | Cellectis S.A. | 100.00 | 2 | |
| DRTS | Alpha Tau Medical Ltd. | 100.00 | 2 | |
| IBIO | iBio, Inc. | 100.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| TLSA | Tiziana Life Sciences Ltd | 100.00 | 2 | |
| CRSP | CRISPR Therapeutics AG | 100.00 | 1 | ['customer', 'supplier'] |
| BMYMP | Bristol-Myers Squibb Co | 100.00 | 1 | ['customer'] |
| BEAM | Beam Therapeutics Inc. | 100.00 | 1 | ['customer'] |
| CRBU | Caribou Biosciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| HOWL | Werewolf Therapeutics, Inc. | 100.00 | 2 | |
| DTIL | Precision BioSciences, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| EMMA | Emmaus Life Sciences, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | ['customer', 'supplier'] |
| CPMV | Mosaic ImmunoEngineering, Inc. | 100.00 | 2 | |
| NBP | NovaBridge Biosciences | 100.00 | 2 |